Drug Approval | December 10, 2021
China approves Brii Bio’s antibody combination to neutralise Covid-19
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
The medicine is now approved for eight indications across five different types of cancer in China.
The DGTR has recommended US $ 3.2 per kg and US $ 3.55 per kg duty on imports
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Subscribe To Our Newsletter & Stay Updated
